Redeye comments on Oncopeptides' Q2 report. Sales amounted to SEK31.
Redeye provides its first take on Oncopeptides' Q2 report 2026.
Oncopeptides has announced an exclusive distribution and commercialization agreement with Salus for its multiple myeloma drug, Pepaxti, cove...
Redeye comments on Oncopeptides’ Q1 report. Sales amounted to SEK25m, an increase by 37% versus Q4 2025.
Redeye provides its first take on Oncopeptides' Q1 report 2026.
Redeye provides a brief comment on Oncopeptides' decision to submit a type II variation to expand the Pepaxti label to include third-line tr...
Redeye comments on Oncopeptides’ Q4 report. Sales declined by 8% versus Q3 2025 when growth was expected.
Redeye comments on Oncopeptides Q4 report, whose topline has already been communicated.
Redeye updates its base case based on lower-than-expected Q4 2025 sales and the company's new financial targets.
Redeye summarises the key takeaways from Oncopeptides’ Capital Markets Update on November 13, 2025.
Redeye comments on Oncopeptides’ 3rd quarter report.
Redeye provides its first take on Oncopeptides' Q3 report 2025.
Redeye is not surprised by the high subscription rate, considering the share has traded above the strike price.
Redeye comments on the real-world data from Spain and Italy, which demonstrated meaningful objective response rates.
Oncopeptides (ONCO) is a Swedish biotech that aims to develop and commercialise therapies for difficult-to-treat cancers, with a focus on ha...
Redeye comments on Oncopeptides’ 2nd quarter report, which saw significant sales progress in the core German, Spanish, and Italian markets.
The sales number for Q2 had already been communicated and was slightly above our forecast.
Redeye comments on the partnership with SD Pharma in Spain, which will broaden physician reach of Pepaxti.
Redeye is growing more optimistic about the investment case in Oncopeptides after two news items this week: the inclusion of Pepaxti in the ...
Redey comments on Oncopeptides’ first quarter report 2025.
Redeye provides its first take on Oncopeptides' Q1 report 2025, published this morning.
Revenues in Q4 came in at SEK10m, slightly softer than we had estimated, albeit still showing growth, mainly in Germany.
Redeye's provides its initial take on Oncopeptides’ year-end report, which came in slightly softer than we had estimated, albeit still showi...
Redeye comments on the positive results from a US study of melfufen in the intended target population, which demonstrated a good safety prof...
Redeye provides a brief comment on Pepaxti's market access in Italy.
Redeye comments on Oncopeptides Q3 report 2024. Revenues in Q3 increased slightly compared to Q2, but product sales declined.
Redeye comments on Oncopeptides’ licensing deal for Pepaxti in South Korea.
Redeye provides a brief comment on the selection of a new drug candidate.
Redeye comments on Oncopeptides' Q1 report, which had few surprises in terms of financials.
Redeye comments on the outcome of Oncopeptide's rights issue.
Redeye comments on the decision of NICE not to recommend Pepaxti in the UK, which is not unexpected.
Redeye initiates coverage of Oncopeptides, a commercial-stage biotech company focusing on multiple myeloma.
